Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8BOFB)

Drug Name

ADP-A2M10 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 1	[1]
Head and neck cancer	2D42	Phase 1	[1]
Melanoma	2C30	Phase 1	[1]
Non-small-cell lung cancer	2C25	Phase 1	[2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanoma-associated antigen 10 (MAGEA10)	TT1VNVM	MAGAA_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

References

1	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
2	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
3	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.